What is the recommended dosing regimen for fluvoxamine, including starting dose, titration schedule, maximum dose, and adjustments for hepatic impairment, elderly patients, and insomnia?

Fluvoxamine Dosing

Start fluvoxamine at 50 mg once daily at bedtime in adults, increase by 50 mg increments every 4-7 days as tolerated to a target of 100-300 mg/day (maximum 300 mg/day), with doses above 100 mg/day split into two divided doses (larger dose at bedtime). 1

Adult Dosing Algorithm

Starting Dose:

• 50 mg once daily at bedtime 1

Titration Schedule:

• Increase by 50 mg increments every 4-7 days as tolerated 1
• Therapeutic range: 100-300 mg/day 2
• Maximum dose: 300 mg/day 1

Dosing Administration:

• Doses ≤100 mg/day: single dose at bedtime
• Doses >100 mg/day: split into two divided doses, with the larger dose given at bedtime 1
• Administer on empty stomach to maximize effectiveness 3

The FDA labeling establishes this as the standard approach 1. Research supports that higher doses (100-150 mg/day) show significantly better response rates (73.7%) compared to lower doses (50-75 mg/day, 47.1% response) 4. Most patients achieve therapeutic benefit within 6 weeks at adequate doses 4.

Pediatric Dosing (Ages 8-17)

Starting Dose:

• 25 mg once daily at bedtime 1

Titration:

• Increase by 25 mg increments every 4-7 days as tolerated 1
• Therapeutic range: 50-200 mg/day 1

Maximum Doses:

• Children ≤11 years: 200 mg/day maximum 1
• Adolescents 12-17 years: up to 300 mg/day (adult maximum) may be needed 1

Important Considerations:

• Female children may achieve therapeutic effect at lower doses 1
• Doses >50 mg/day should be split into two divided doses (larger dose at bedtime) 1
• Children show 2-3 fold higher plasma concentrations than adolescents at equivalent doses, requiring careful titration 1

Elderly and Hepatically Impaired Patients

Dosing Modifications Required:

• Start at lower initial doses 1
• Use slower titration schedules 1
• Elderly patients show 40% higher maximum plasma concentrations and 50% reduced clearance 1
• Mean elimination half-life increases from 15.6 hours in young adults to 25.9 hours in elderly 1

The guideline evidence for elderly patients with Alzheimer's disease suggests starting at 50 mg twice daily with a maximum of 150 mg twice daily 2, though this may be conservative for general elderly populations. Exercise particular caution with benzodiazepine co-administration (alprazolam, triazolam), as fluvoxamine significantly inhibits their metabolism 2.

Hepatic Impairment

• 30% decrease in fluvoxamine clearance occurs with hepatic dysfunction 1
• Modify initial dose and subsequent titration 1
• No specific dosing algorithm provided in FDA labeling, but clinical judgment suggests starting at 25 mg daily with slower titration

Renal Impairment

• No dose adjustment required 1
• No accumulation observed in patients with creatinine clearance 5-45 mL/min 1

Management of Insomnia

If insomnia occurs during treatment:

• Administer entire daily dose (or larger portion) at bedtime rather than morning 5
• Single nighttime dosing shows fewer side effects leading to dropout compared to twice-daily or single daytime dosing 5
• Avoid giving second dose after 3 PM if using divided dosing to minimize insomnia risk (similar principle to bupropion) 2

Discontinuation

Taper gradually rather than abrupt cessation 1:

• Discontinue over 10-14 days to limit withdrawal symptoms 2
• Fluvoxamine is associated with discontinuation syndrome (dizziness, fatigue, nausea, sensory disturbances) 6
• If intolerable symptoms occur during taper, resume previous dose and decrease more gradually 1

Duration of Treatment

• Adequate trial requires 4-8 weeks at maximum tolerated dose 2
• For OCD specifically, efficacy beyond 10 weeks is not well-documented in controlled trials, but continuation is reasonable for responders 1
• After 9 months, consider dose reduction to reassess need for continued treatment 2
• More than 80% of responders show improvement by 6 weeks 4

Critical Drug Interactions

Contraindicated:

• MAOIs (risk of serotonin syndrome) 7

Significant Interactions:

• Potent CYP1A2 inhibitor: major interactions with drugs metabolized by this pathway 6, 8
• Moderate CYP3A4 and CYP2C19 inhibitor 6, 8
• Reduce alprazolam or triazolam dose by 50% when co-administered 2
• Minimal effect on CYP2D6 (unlike paroxetine and fluoxetine) 6, 8

Common Pitfalls

• Inadequate dosing: Many patients require 100-300 mg/day for optimal response; 50 mg is typically insufficient 4
• Insufficient trial duration: Allow at least 6 weeks at therapeutic dose before declaring treatment failure 4
• Abrupt discontinuation: Always taper to avoid withdrawal syndrome 1
• Overlooking drug interactions: Fluvoxamine has extensive CYP450 interactions, particularly CYP1A2 8
• Not adjusting for age: Elderly patients require dose modification due to 50% reduction in clearance 1